SPARC Company Description
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally.
It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company’s products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures.
In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson’s disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer’s disease.
Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial.
Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials.
The company was incorporated in 2006 and is based in Mumbai, India.
![Sun Pharma Advanced Research Company logo](https://img.stockanalysis.com/logos1/NSE/SPARC.png)
Country | India |
Founded | 2006 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 409 |
CEO | Anilkumar Raghavan |
Contact Details
Address: 17/B, Mahal Industrial Estate Mumbai, 400093 India | |
Phone | 91 22 6645 5645 |
Website | sparc.life |
Stock Details
Ticker Symbol | SPARC |
Exchange | National Stock Exchange of India |
Fiscal Year | April - March |
Reporting Currency | INR |
ISIN Number | INE232I01014 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Anilkumar Raghavan | Chief Executive Officer |
Anup Rathi | Chief Financial Officer |
Dr. Nitin Dharmadhikari | Chief Operating Officer |
Jaydeep Issrani | Senior General Manager of Business Development, Corporate Communication and Investor Relations |
Kajal K. Damania | Company Secretary and Compliance Officer |
Shanta Gupta | Chief Human Resource Officer |
Siu-Long Yao | Head Clinical Development |
Dr. Nitin K. Damle Ph.D. | Chief Innovation Officer |
Dr. Yashoraj Zala | Head of Drug Delivery Systems |
Dr. Vikram K. Ramanathan | Head of Preclinical Development |